53 related articles for article (PubMed ID: 12768069)
21. By reducing production of vascular endothelial growth factor octreotide improves the peritoneal vascular alterations induced by hypertonic peritoneal dialysis solution.
Günal AI; Celiker H; Akpolat N; Ustündag B; Duman S; Akcicek F
Perit Dial Int; 2002; 22(3):301-6. PubMed ID: 12227386
[TBL] [Abstract][Full Text] [Related]
22. By reducing TGF beta 1, octreotide lessens the peritoneal derangements induced by a high glucose solution.
Günal AI; Duman S; Sen S; Unsal A; Terzioğlu E; Akçiçek F; Basci A
J Nephrol; 2001; 14(3):184-9. PubMed ID: 11439742
[TBL] [Abstract][Full Text] [Related]
23. Vascular endothelial growth factor in peritoneal dialysis: a longitudinal follow-up.
Zweers MM; Struijk DG; Smit W; Krediet RT
J Lab Clin Med; 2001 Feb; 137(2):125-32. PubMed ID: 11174469
[TBL] [Abstract][Full Text] [Related]
24. Comparison of peritoneal equilibration test with 2.27% and 3.86% glucose dialysis solution.
Cara M; Virga G; Mastrosimone S; Girotto A; Rossi V; D'Angelo A; Bonfante L
J Nephrol; 2005; 18(1):67-71. PubMed ID: 15772925
[TBL] [Abstract][Full Text] [Related]
25. Vascular endothelial growth factor (VEGF) levels in peritoneal dialysis effluent.
Selgas R; del Peso G; Bajo MA; Molina S; Cirugeda A; Sánchez-Tomero JA; Castro MJ; Castro MA; Vara F
J Nephrol; 2001; 14(4):270-4. PubMed ID: 11506249
[TBL] [Abstract][Full Text] [Related]
26. The effect of oxidative stress inhibition with trimetazidine on the peritoneal alterations induced by hypertonic peritoneal dialysis solution.
Günal AI; Celiker H; Ustundag B; Akpolat N; Dogukan A; Akcicek F
J Nephrol; 2003; 16(2):225-30. PubMed ID: 12768069
[TBL] [Abstract][Full Text] [Related]
27. Biocompatible peritoneal dialysis solutions: do we have one?
Chaudhary K; Khanna R
Clin J Am Soc Nephrol; 2010 Apr; 5(4):723-32. PubMed ID: 20093342
[TBL] [Abstract][Full Text] [Related]
28. [Function of the peritoneum in hyperglycemic conditions].
Czyzewska K
Postepy Hig Med Dosw; 1994; 48(3):291-307. PubMed ID: 7971603
[TBL] [Abstract][Full Text] [Related]
29. [How to use the peritoneum as a dialysis membrane. Methods of surveillance, criteria of efficacy and longevity as a dialysis membrane, consequences with respect to techniques of peritoneal dialysis].
Verger C
Nephrologie; 1995; 16(1):19-31. PubMed ID: 7700417
[TBL] [Abstract][Full Text] [Related]
30. Unfavorable Effects of Peritoneal Dialysis Solutions on the Peritoneal Membrane: The Role of Oxidative Stress.
Roumeliotis S; Dounousi E; Salmas M; Eleftheriadis T; Liakopoulos V
Biomolecules; 2020 May; 10(5):. PubMed ID: 32423139
[TBL] [Abstract][Full Text] [Related]
31. Vascular endothelial growth factor-mediated peritoneal neoangiogenesis in peritoneal dialysis.
Shi Y; Hu Y; Cui B; Zhuang S; Liu N
Perit Dial Int; 2022 Jan; 42(1):25-38. PubMed ID: 33823711
[TBL] [Abstract][Full Text] [Related]
32. Neoangiogenesis in the peritoneal membrane.
Krediet RT; Zweers MM; van der Wal AC; Struijk DG
Perit Dial Int; 2000; 20 Suppl 2():S19-25. PubMed ID: 10911638
[TBL] [Abstract][Full Text] [Related]
33. What can we do to preserve the peritoneum?
Krediet RT; Zweers MM; van Westrhenen R; Ho-dac-Pannekeet MM; Struijk DG
Perit Dial Int; 2003 Dec; 23 Suppl 2():S14-9. PubMed ID: 17986535
[TBL] [Abstract][Full Text] [Related]
34. The pathophysiology of the peritoneal membrane.
Devuyst O; Margetts PJ; Topley N
J Am Soc Nephrol; 2010 Jul; 21(7):1077-85. PubMed ID: 20448020
[TBL] [Abstract][Full Text] [Related]
35. Peritoneal dialysis in diabetic patients.
Lee HB; Chung SH; Chu WS; Kim JK; Ha H
Am J Kidney Dis; 2001 Oct; 38(4 Suppl 1):S200-3. PubMed ID: 11576955
[TBL] [Abstract][Full Text] [Related]
36. Oxidative Stress in Patients Undergoing Peritoneal Dialysis: A Current Review of the Literature.
Liakopoulos V; Roumeliotis S; Gorny X; Eleftheriadis T; Mertens PR
Oxid Med Cell Longev; 2017; 2017():3494867. PubMed ID: 29750088
[TBL] [Abstract][Full Text] [Related]
37. Peritoneal equilibration testing: Your questions answered.
Gu J; Bai E; Ge C; Winograd J; Shah AD
Perit Dial Int; 2023 Sep; 43(5):361-373. PubMed ID: 36350033
[TBL] [Abstract][Full Text] [Related]
38. Relative Contributions of Pseudohypoxia and Inflammation to Peritoneal Alterations with Long-Term Peritoneal Dialysis Patients.
Krediet RT; Parikova A
Clin J Am Soc Nephrol; 2022 Aug; 17(8):1259-1266. PubMed ID: 35168992
[TBL] [Abstract][Full Text] [Related]
39. Preservation and modulation of peritoneal function. A potential role of pyruvate and betaine.
Gotloib L
Contrib Nephrol; 2009; 163():74-81. PubMed ID: 19494598
[TBL] [Abstract][Full Text] [Related]
40. Glucotoxicity of the peritoneal membrane: the case for VEGF.
De Vriese AS; Mortier S; Lameire NH
Nephrol Dial Transplant; 2001 Dec; 16(12):2299-302. PubMed ID: 11733619
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
